Probiotic Supplement Reduces Blood Biomarker and Improves Cognitive Scores in Early Alzheimer’s Trial
In a randomized, double‑blind trial conducted in South Korea, 87 older adults with early cognitive impairment received a multistrain probiotic (KL‑P301) for 24 weeks. The supplement lowered plasma pTau181 levels and improved performance on several cognitive tests compared with placebo.
Key Takeaways
- KL‑P301 contains Bifidobacterium animalis, Limosilactobacillus fermentum, and Levilactobacillus brevis.
- Participants showed a significant reduction in plasma pTau181 after 24 weeks.
- Visuospatial construction and visual memory scores improved relative to placebo.
- IL‑1β, a pro‑inflammatory cytokine, decreased more in the probiotic group.
- Results suggest gut microbiota may influence early Alzheimer’s pathology.
| Metric | Value | Why it matters |
|---|---|---|
| Study location | South Korea | Represents a non‑Western cohort. |
| Participants | 87 (40 probiotic, 47 placebo) | Adequate power for pilot findings. |
| Intervention duration | 24 weeks | Standard period for cognitive trials. |
| Biomarker reduced | pTau181 | Early indicator of Alzheimer’s pathology. |
| Cognitive domain improved | Visuospatial construction & visual memory | Key deficits in prodromal Alzheimer’s. |
Study Design and Participants
The trial was nested within the Gwangju Alzheimer's Disease and Related Dementias (GARD) cohort, a longitudinal study in South Korea. Participants were randomly assigned to receive either the probiotic or a placebo in a double‑blind fashion.
Probiotic Composition
KL‑P301 is a powder that can be taken alone or dissolved in water. It contains three bacterial strains: Bifidobacterium animalis, Limosilactobacillus fermentum, and Levilactobacillus brevis.
Cognitive Outcomes
After 24 weeks, the probiotic group scored significantly higher on the Clinical Dementia Rating system. They also performed better on tasks assessing visuospatial construction, spatial organization, and complex shape drawing, although not all comparisons reached statistical significance.
Biomarker Findings
Plasma levels of phosphorylated tau (pTau181) fell markedly in the probiotic group relative to placebo. pTau181 is a blood‑based marker that rises before dementia symptoms appear and reflects abnormal tau folding in the brain.
Inflammatory Markers
Most inflammatory markers changed only modestly, but IL‑1β decreased more in the probiotic group. This suggests a selective anti‑inflammatory effect on specific cytokine pathways.
Implications and Future Directions
While the trial does not prove that probiotics directly reduce tau tangles in the brain, it adds to evidence that the gut microbiome may influence early neurodegenerative processes. Authors call for larger trials incorporating tau/amyloid‑β PET imaging to confirm durability and clinical relevance.
Why it matters
Early intervention in Alzheimer’s disease is critical. If gut microbiota can modulate blood biomarkers and preserve cognitive function, probiotics could become a low‑risk, non‑pharmacological strategy for individuals in the prodromal stage. The findings also highlight the need to understand how gut health affects systemic inflammation and brain integrity.
Frequently Asked Questions
What is pTau181 and why is it important?
pTau181 is a phosphorylated form of tau protein measured in blood. Elevated levels precede dementia symptoms and indicate early Alzheimer’s pathology.
How many participants completed the probiotic arm of the study?
Forty participants completed the 24‑week probiotic intervention.
Which bacterial strains were included in the probiotic?
The supplement contained Bifidobacterium animalis, Limosilactobacillus fermentum, and Levilactobacillus brevis.
Did the study show a direct reduction of brain tau tangles?
No. The trial measured blood biomarkers and cognitive scores; it did not assess tau tangles in brain tissue.
What are the next steps for research?
Researchers plan larger, longer trials with imaging biomarkers to confirm the durability of the probiotic’s effects and to explore its utility as a preventive measure.
Bottom Line
In a 24‑week, double‑blind trial, a multistrain probiotic lowered plasma pTau181 and improved visuospatial cognition in older adults with early cognitive decline. Although preliminary, the results support further investigation of gut microbiota modulation as a potential non‑pharmacological approach to mitigate early Alzheimer’s disease.
For more details, see the original study in the Journal of Alzheimer’s Disease.
Reporting based on: original source.
Comments
Post a Comment